BACKGROUND: Molecular testing is recommended as an adjunct to improve the preoperative diagnosis of fine-needle aspiration (FNA) of thyroid nodules. Centrifuged supernatants from FNA samples, which are typically discarded, have recently emerged as a novel liquid-based biopsy for molecular testing. This study evaluates the use of thyroid FNA supernatants for detecting clinically relevant mutations. METHODS: Supernatants from thyroid FNA samples (n = 156) were evaluated. A 50-gene next-generation sequencing (NGS) assay was used, and mutation analysis results from a subset of samples were further compared with those of paired FNA smears and/or cell blocks. RESULTS: All 156 samples yielded adequate DNA (median, 135 ng; range, 11-3180 ng), and 129 of these samples (83%) were successfully sequenced by NGS. The most frequently detected somatic mutations included BRAF and RAS mutations, which were followed by RET, TP53, PTEN, CDKN2A, and PIK3CA mutations. Eleven of 31 cases with an indeterminate cytologic diagnosis and 9 of 12 cases that were suspicious for malignancy had somatic mutations, including the BRAF V600E mutation, which is highly definitive for papillary thyroid carcinoma (PTC). Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC. A comparison of the mutation profiles derived from supernatants with those of paired smears and/or cell blocks in a small subset of cases (n = 8) showed 100% concordance. CONCLUSIONS: This study provides evidence that FNA supernatants can be used as a surrogate for thyroid molecular testing to improve diagnostic accuracy in indeterminate nodules, provide prognostic/predictive information, and improve overall patient management.
INTRODUCTION
The prevalence of thyroid nodules in the adult population is as high as 70%; however, most of these nodules are benign 1, 2 and can be managed conservatively without surgical excision. Thyroid carcinoma, however, is one of the most common endocrine malignancies, and sampling by fine-needle aspiration (FNA) with a cytologic evaluation is typically the mainstay for the diagnosis of these thyroid nodules. Cytologic diagnoses
Cancer Cytopathology March 2019 are classified according to the 6-tiered Bethesda System for Reporting Thyroid Cytopathology, which includes the following categories: (I) nondiagnostic, (II) benign, (III) atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), (IV) follicular neoplasm or suspicious for follicular neoplasm (FN/SFN), (V) suspicious for malignancy, and (VI) malignant. 3 The clinical importance of distinguishing between benign nodules and malignant tumors is to ensure that each patient receives timely and appropriate treatment and to avoid unnecessary surgical resection in patients with benign nodules. The National Comprehensive Cancer Network guidelines recommend repeat FNA for solid lesions within the nondiagnostic category, observation for stable nodules with a benign diagnosis, and surgical excision for nodules diagnosed as suspicious or malignant. 4 However, the malignancy risk rates associated with the indeterminate categories, namely AUS/FLUS and FN/SFN, vary significantly across institutions, and this makes definitive management of these nodules difficult. 5, 6 Consequently, many of these patients undergo surgeries such as lobectomy for a definitive diagnosis, which is usually unnecessary when the nodule is benign unless it is symptomatic. 7 Over the last decade, our understanding of key genetic events involved in the oncogenesis of thyroid malignancies has improved greatly, and this has led to the increasing use of molecular-based testing as an adjunct test to improve the diagnostic accuracy of thyroid FNA and the increased presurgical detection of thyroid cancer. [8] [9] [10] Most commercially available molecular testing options, however, are send-out tests that require a dedicated FNA pass collected in a proprietary medium. Because the adequacy of thyroid FNA can vary significantly among needle passes, the use of a dedicated needle pass for molecular testing without microscopic confirmation of cellular adequacy carries a risk of inadequate sampling and a false-negative result. Although a small subset of these commercially available tests are able to use previously stained cytology smears for analysis 11 and thus ensure sample adequacy, the archival cytologic smears may fall short of meeting sample adequacy requirements for a comprehensive evaluation. Consequently, there is a need for "doing more with less" and optimizing the limited volume of FNA samples for molecular testing to provide clinically relevant genomic information that may guide patient care.
Recently, our group has reported on the ability to repurpose discarded supernatant fluids from centrifuged FNA needle rinses for multiplexed, multigene mutational profiling by next-generation sequencing (NGS). 12 Other studies have shown that substantial amounts of DNA can be extracted and amplified from the centrifuged supernatant fluid of pancreatic-biliary FNA samples and can be used to detect KRAS mutations, even in samples containing few or no cells. 13, 14 Another study used pyrosequencing to detect BRAF mutations from supernatants derived from thyroid FNA samples in BRAF-positive tumors; however, the authors failed to identify mutations in a subset of supernatants corresponding to the BRAF-positive cellular FNA samples. 15 These results raised some concern about the possibility of false-negative results when one is performing molecular testing from a substrate that does not undergo direct microscopic evaluation. These authors, however, used separate methodologies for mutation detection for the 2 specimen preparations; this may account for the discordance, which was likely due to differences in analytical sensitivity.
In this study, we evaluate the feasibility of using discarded supernatant fluids from thyroid FNA samples for detecting clinically relevant mutations by NGS, a highly sensitive, multiplexed, multigene mutation analysis platform. We further evaluate the utility of supernatant samples as a valid and possibly preferred substrate by comparing their performance with that of corresponding paired FNA smears and/or cell blocks.
MATERIALS AND METHODS

Sample Selection
After approval by the institutional review board, centrifuged supernatant fluids of 156 FNA samples from primary thyroid and/or metastatic sites of 134 patients were collected. The sites included the thyroid or thyroid surgical bed (n = 122), lymph nodes (n = 32), parotid gland (n = 1), and lung (n = 1), and they included all 6 Bethesda diagnostic categories. The FNA procedures were performed in house under ultrasound guidance by a radiologist (except for 1 case of transthoracic lung FNA, which was performed by an interventional radiologist under computed tomography guidance). All FNA procedures were sampled by 2 to 3 passes with 20-to 25-gauge needles. A rapid onsite evaluation was performed by a cytopathologist to assist in sampling adequacy. As
Cancer Cytopathology March 2019 depicted in Figure 1 , expelled tissue from FNA samples were processed as direct smears and stained with the DiffQuik and/or Papanicolaou stain as previously described. 16 The residual cellular material in the needle was then rinsed into 10 mL of Roswell Park Memorial Institute 1640 (Life Technologies, Carlsbad, California) and centrifuged at 1500 rpm for 10 minutes to obtain a cell pellet, which was processed either as a cytospin preparation or as a formalin-fixed, paraffin-embedded cell block. 17 The supernatant fluids from the needle rinse were stored at 4°C after centrifugation until the cytologic diagnosis was finalized and then were collected for DNA extraction and subsequent molecular testing. To evaluate the feasibility of using an FNA supernatant as a substitute for the FNA cellular specimen (ie, smears/cell block), a subset of cases (n = 19) were selected for parallel NGS analysis from the corresponding FNA. The cases were selected on the basis of the availability of a cell block or additional stained smears that could be used for NGS analysis and met our cellularity (1500 cells) and minimum tumor fraction requirements (20% tumor) for NGS analysis.
DNA Extraction
DNA was extracted from 4 mL of the FNA centrifuged fluids with the QIAsymphony automatic DNA extraction platform (Qiagen, Germantown, Maryland) and the Qiagen circulating DNA kit (Qiagen) according to the manufacturer's guidelines. For the cytology specimens, tissue was scraped from a single direct smear or cell block section with a scalpel blade by manual macrodissection, and the scraped tissue was incubated in PicoPure reconstitution buffer (Arcturus, Mountain View, California) according to the manufacturer's guidelines. The DNA was purified with AMPure beads (Agencourt AMPure XP kit; Agencourt Biosciences, Beverly, Massachusetts). Extracted DNA (eluted in 60 µL) was quantified with the Qubit DNA high-sensitivity assay kit (Thermo Fisher Scientific, Waltham, Massachusetts) and analyzed for the size range by gel electrophoresis with Agilent High Sensitivity D5000 ScreenTape (Agilent, Santa Clara, California).
Mutation Analysis
The FNA supernatant DNA and cellular DNA were used to prepare libraries with the Ion AmpliSeq Cancer Hotspot Panel (version 2; Thermo Fisher Scientific), which interrogates 2855 mutational hotspots in the coding sequences of 50 cancer-related genes, as described previously. 17 Appropriate dilutions were prepared, when needed (n = 132), to achieve the manufacturerrecommended 10 ng (0.91 ng/µL) DNA input for library preparation. If the DNA concentration was suboptimal (n = 24), DNA was used "as is" without any further dilution. Each library was diluted to 50 pM and pooled Cancer Cytopathology March 2019 equally for sequencing on the Ion Proton sequencer (Thermo Fisher Scientific). 18 A minimum of 300,000
reads with a quality score of AQ20 (1 Table 1 ). However, for variant calling, a minimum 250× sequencing depth and 25× variant coverage were applied to the current bioinformatics workflow, and all variants detected with an allelic frequency ≤5% were manually evaluated before reporting. A subset of cases (n = 12) that had mutations with a low allelic frequency (<10% VAF) and a subset of BRAF mutation-negative cases (n = 6; AUS/FLUS, suspicious for papillary thyroid carcinoma [PTC] , and primary/metastatic PTC) were further evaluated for BRAF c.1799T>A p.V600E and NRAS c.181C>A p.Q61K, as needed, via ultrasensitive droplet digital polymerase chain reaction (ddPCR; limit of detection, 0.1% VAF). Genotyping was performed with 10 ng of DNA and commercial primers and probes on the QX100 ddPCR system (BioRad, Hercules, California). Polymerase chain reaction (PCR) components were separated into individual reaction droplets with the QX100 droplet generator (BioRad). The PCR amplification conditions were 95°C for 10 minutes, 40 cycles of 94°C for 30 seconds, and 55°C for 60 seconds, which was followed by enzyme inactivation at 98°C for 10 minutes. After thermal cycling, droplets were read in the QX100 droplet reader (Bio-Rad), and the digital PCR data were analyzed with QuantaSoft analytical software (Bio-Rad).
Data Analysis
Statistical analysis was performed with the 2-tailed Mann-Whitney test, when the sample size was adequate, to compare the DNA yield of each cytology category (ie, AUS/FLUS, suspicious for malignancy, and malignant) with that of the benign category. The DNA yield of paired FNA cytologic cellular specimens and centrifuged supernatant fluids was analyzed with the Wilcoxon matched pairs signed rank test. Correlations between 1) mutation detection by NGS and ddPCR, and 2) mutations detected in paired FNA cellular DNA and supernatant DNA were performed with the Pearson correlation coefficient. A P value < .05, calculated with the 2-tailed test, was considered significant. Linear regression was performed for paired NGS and ddPCR mutation detection and for paired FNA cellular and supernatant DNA. Data analyses were performed with GraphPad Prism software (version 7.03; GraphPad, La Jolla, California).
RESULTS
DNA Yield in Centrifuged Supernatants of FNA Samples
All 156 FNA supernatant samples yielded adequate amounts of DNA; they included 10 cases that were nondiagnostic by cytology. The median DNA yield obtained from 4 mL of supernatant (roughly half the total amount of supernatant available) was 134.7 ng (range, 10.6-3180 ng; Table 1 ). No significant difference in DNA yields was observed between different cytologic categories when they were compared with the yield of the benign group. Notably, all 156 samples had a DNA yield greater than 10 ng (total DNA in 60 µL), which is the manufacturer-recommended minimum threshold for NGS input DNA. A qualitative analysis of the supernatant DNA showed a dominant single peak of approximately 4.7 kb by electrophoretic analysis, which was indicative of high-molecular weight genomic DNA, with minimal amounts of cell-free DNA seen as a questionable peak at 0.1 kb (Fig. 2) .
Mutational Analysis Using NGS and ddPCR
Of the 156 samples, 132 had an optimal DNA input of 10 ng for Ion Proton NGS library preparation, whereas the remaining 24 samples had concentrations slightly below the required concentration, which resulted in a suboptimal input (<10 ng) for NGS library preparation ( were successfully amplified to generate an adequate library for downstream sequencing, whereas the remaining 23 samples (17.4%) resulted in a suboptimal library. The 24 samples with a suboptimal DNA input (range, 1.9-9.2 ng) were used to generate libraries for sequencing; 13 of these samples (54.2%) successfully generated an adequate library, whereas 11 samples (45.8%) resulted in a suboptimal library (Fig. 3) . NGS was performed on all 134 libraries (122 adequate and 12 suboptimal).
Five samples with suboptimal libraries failed sequencing, whereas the remaining 129 samples were successfully sequenced with an average of 1,368,450 reads with a quality score of AQ20 per sample and a mean sequencing depth of 6056×. In addition, we confirmed BRAF c.1799T>A p.V600E (n = 17) and NRAS c.181C>A p.Q61K mutations (n = 1) in 18 cases with a highly sensitive ddPCR assay (sensitivity, 0.1% VAF). The obtained linear regression indicates 100% concordance between the mutations The heatmap shows the mutation pattern of the 9 commonly mutated genes in thyroid carcinoma seen in our cohort. Each column represents a unique sample, and each row represents a specific mutation. The number inside each box represents the variant allelic frequency, and an asterisk indicates whether the mutation has been independently confirmed by droplet digital polymerase chain reaction. The vertical bar graph shows the total number of somatic mutations detected in each sample. The horizontal bar graph shows the percentage of cases harboring a specific mutation.
detected and the corresponding allelic frequencies by NGS and ddPCR (R 2 = 0.9531; P < .0001; Fig. 4 ).
Five samples that had a nondiagnostic cytologic diagnosis were successfully sequenced with adequate sequencing metrics; germline polymorphisms were detected, but none of the samples had any somatic mutations. Of the 15 samples that had a benign diagnosis, 11 (73.3%) did not show any somatic mutation. Mutations in RAS (HRAS c.181C>A p.Q61K, NRAS c.181C>A p.Q61K, and NRAS c.182A>G p.Q61R) were detected in 4 samples (Fig. 5 ). An NRAS mutation (c.181C>A p.Q61K) that had a low VAF was confirmed independently by ddPCR.
In the indeterminate cytology category, most samples (20 of 31 [64.5%]) had no mutation detected (Fig. 6) . Seven cases had RAS mutations (HRAS c.182A>G p.Q61R and NRAS c.182A>G p.Q61R), 3 cases had nonsense mutations in PTEN (c.640C>T p.Q214*, c.892C>T p.Q298*, c.955_958del p.T319*, and c.1003C>T p.Q335*), and 2 cases of AUS/FLUS were found to harbor BRAF c.1799T>A p.V600E mutations. Because of the relatively low VAF seen in these latter 2 cases, ddPCR was performed, and it confirmed the BRAF mutation in 1 sample; however, the other case did not have sufficient DNA for further evaluation. Thirteen patients (42%) in the indeterminate group had no further follow-up; they included 4 patients who had mutations in NRAS, HRAS, PTEN, and BRAF. Seven patients had stable nodules on follow-up, and 4 of these patients had mutations in NRAS, HRAS, and PTEN. The remaining 11 patients had surgical follow-up: 1 of 3 patients diagnosed as having benign colloid nodules had a mutation in HRAS, 1 of 3 patients with PTC had a BRAF mutation, and the 1 patient diagnosed with follicular carcinoma had an NRAS mutation. However, the 2 patients with follicular variants of PTC, the 1 patient with follicular adenoma, and the 1 patient with an atypical Hürthle cell neoplasm did not have any mutations detected (Fig. 6) . 
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Of the 12 samples in the suspicious for malignancy category, most (9 of 12 [75%]) had somatic mutations (Fig. 7) . The BRAF c.1799T>A p.V600E mutation was the most commonly detected mutation and was present in 7 samples that were diagnosed as suspicious for PTC. KRAS c.38G>A p.G13D was detected in 1 sample diagnosed as suspicious for metastatic carcinoma; it was subsequently diagnosed as metastatic adenocarcinoma from a colorectal primary. TP53 mutations (c.659A>G p.Y220C and c.747G>T p.R249S) were detected in 2 samples, and a CDKN2A mutation (c.238C>T p.R80*) was detected in 1 sample. Among these patients, 8 had surgical follow-up that showed PTC, and 6 of them had a BRAF c.1799T>A p.V600E mutation detected in the supernatant (Fig. 7) . One sample with a low-level BRAF c.1799T>A p.V600E mutation was confirmed by ddPCR, whereas another sample diagnosed as suspicious for PTC with no mutation detected was also confirmed to be negative for a BRAF mutation by ddPCR (Fig. 7) . Two patients were lost to follow-up, including 1 who had a BRAF c.1799T>A p.V600E mutation detected. The 2 remaining patients had a subsequent surgical biopsy, the testing of which confirmed the mutations detected in the supernatant.
In the malignant category, we evaluated 40 samples from a primary thyroid site (thyroid and thyroid surgical bed) with a diagnosis of PTC (n = 32), medullary thyroid carcinoma (MTC; n = 4), follicular thyroid carcinoma (FTC; n = 2), or anaplastic thyroid carcinoma (ATC; n = 2). Most of these samples (34 of 40 [85%]) had 1 somatic mutation detected, 2 of the 40 samples (5%) had 2 mutations detected, whereas 4 samples (10%) had no mutation detected (Fig. 8) .
The most common mutation detected in this category was BRAF c.1799T>A p.V600E, which was seen in 29 PTC cases. RET mutations (c.1853G>C p.C618S, c.2647_2648delinsTT p.A883F, and c.2753T>C p.M918T) were detected in 3 MTC samples, RAS mutations (HRAS c.182A>G p.Q61R, KRAS c.35G>T p.G12V, and NRAS c.182A>G p.Q61R) were detected in 3 samples (1 MTC, 1 FTC, and 1 ATC, respectively), and TP53 mutations (c.514G>T p.V172F and c.839G>C p.R280T) were detected in 2 samples (1 PTC and 1 ATC; Fig. 8 ).
In addition, our study cohort included 30 samples from metastatic sites in patients with known thyroid carcinoma, including metastatic PTC (n = 20), metastatic MTC (n = 4), metastatic FTC (n = 3), and metastatic ATC (n = 3). Most of these samples (22 of 30 [73.3%]) showed 1 somatic mutation, and 2 samples (6.7%) had 2 mutations, whereas 6 samples (20%) had no mutation detected (Fig. 9) . The most common mutation detected in this category was BRAF c.1799T>A p.V600E, which was present in 16 metastatic PTC cases and 1 metastatic ATC case. RAS mutations (HRAS c.182A>G p.Q61R, KRAS c.38G>A p.G13D, and NRAS c.182A>G p.Q61R) were detected in 2 FTC cases and 2 MTC cases. Mutations in RET (c.2753T>C p.M918T), TP53 (c.577C>T p.H193Y and c.839G>C p.R280T), PIK3CA (c.1633G>A p.E545K), and CDKN2A (c.220G>A p.D74N) were detected in 5 cases (Fig. 9) . Four metastatic PTC samples with very low VAFs (1%-2%) for BRAF c.1799T>A p.V600E were confirmed independently by ddPCR. 
The study cohort included 8 patients with concurrently acquired paired samples (either primary and metastatic sites or metastatic site A and metastatic site B) for whom the mutation detected could be compared between the paired samples. All 8 pairs showed 100% concordance in the mutations detected, with varying allelic frequencies for the somatic mutations (Table 2) . Although the allelic frequencies of polymorphisms remained the same (approximately 50% or 100%) between paired sites, the variation in VAF for somatic mutations correlated with the difference in the tumor fraction in the FNA specimen.
We further compared a subset of supernatant samples (n = 19) with corresponding paired FNA cellular material (smear or cell block sections). The DNA yield from the centrifuged supernatant fluids was significantly higher than that from the corresponding cytologic cellular specimen (P < .01; Table 3 ). The low DNA yield from the cytologic smears/cell blocks resulted in the NGS failure of 11 of 19 samples (58%) either in library preparation or during sequencing.
The remaining 8 samples (42%) that were successfully sequenced showed 100% concordance with the mutation profile of the corresponding supernatant sample (Table 3 and Fig. 10 ).
DISCUSSION
The Bethesda System for Reporting Thyroid Cytopathology has significantly improved and standardized cytologic diagnoses for thyroid nodules. However, the diagnostic challenge of cases with indeterminate cytologic findings causes uncertainty in the clinical management of these patients, with options ranging from clinical observation to repeat FNA to surgical lobectomy. The National Comprehensive Cancer Network guidelines and the 2015 American Thyroid Association recommend molecular testing as an adjunct to help to improve the diagnosis of cases with an indeterminate thyroid cytology. 4, 19 In addition, there are emerging data that support molecular testing in the setting of thyroid carcinomas to help with prognostication and patient management. 20 Most commercially available molecular tests for thyroid Cancer Cytopathology March 2019 cytology specimens involve collecting additional needle passes in a proprietary medium that is sent to reference laboratories for testing. This approach is not always feasible and/or adequate for testing and also increases the turnaround time (TAT) because of the logistics involved in a send-out test. The TAT for commercially available thyroid molecular testing usually ranges from 10 to 14 days. 21, 22 In contrast, the TAT for a targeted ddPCR assay from the supernatant performed in house is 2 days from the day of collection of the specimen, whereas the TAT for a comprehensive NGS assay is approximately 5 to 7 days. The previously outlined workflow using supernatants would dramatically decrease the TAT of molecular testing of thyroid nodules and thus allow appropriate patient management in a timely fashion. Recent studies have reported on the feasibility of using residual liquid-based cytology from thyroid FNA samples to perform molecular testing; this is akin to human papillomavirus testing from residual liquid-based cytology in cervical cytology samples. [23] [24] [25] [26] [27] A recent study has reported the detection of BRAF mutations by Each column represents a unique sample, and each row represents a specific mutation. The number inside each box represents the variant allelic frequency, and an asterisk indicates whether the mutation has been independently confirmed by droplet digital polymerase chain reaction. The vertical bar graph shows the total number of somatic mutations detected in each sample. The horizontal bar graph shows the percentage of cases harboring a specific mutation. metATC indicates metastatic anaplastic thyroid carcinoma; metFTC, metastatic follicular thyroid carcinoma; metMTC, metastatic medullary thyroid carcinoma; metPTC, metastatic papillary thyroid carcinoma. Cancer Cytopathology March 2019 pyrosequencing in a subset of supernatants from FNA centrifuged needle rinses of thyroid nodules. 15 In this study, we show that previously discarded supernatants from thyroid FNA needle rinses can provide substantial amounts of DNA for comprehensive mutational profiling by NGS for multiple genes, even when the corresponding FNA smear/cell block material is sparsely cellular and precludes further molecular testing. Our results also indicate that mutational profiling of these FNA supernatant samples can be used as a presurgical screening test in cases with an indeterminate cytology to improve diagnostic accuracy without the need for additional needle passes or a repeat biopsy. The mutations detected in our cohort of thyroid supernatant samples closely reflect those reported by The Cancer Genome Atlas (TCGA), 28 with mutations in BRAF and RAS being most frequently detected. BRAF and RAS mutations are also known to be mutually exclusive in thyroid oncogenesis, with rare exceptions, 28, 29 Similarly, most of the BRAF and RAS mutations detected in our study cohort were mutually exclusive, except for a single AUS/FLUS case that showed coexisting BRAF and RAS mutations (Fig. 6 ). This patient had a known history of acral melanoma that did not show any somatic mutations (including the BRAF and HRAS mutations detected in the thyroid FNA supernatant) and had an Cancer Cytopathology March 2019 incidental thyroid nodule that was aspirated. However, no follow-up was available on this patient; therefore, the significance of the BRAF c.1799T>A p.V600E mutation detected in the thyroid supernatant is unknown. Other mutations detected in our study included commonly mutated genes in thyroid carcinomas, such as TP53, RET, PTEN, and PIK3CA. BRAF mutations were found primarily in PTC and a subset of ATC samples, whereas RET mutations were mostly present in MTC. RAS mutations, on the other hand, were found in FTC, ATC, and RET-negative MTC samples, and this is in keeping with the previously reported rates of RAS mutations in different thyroid malignancies. [30] [31] [32] [33] [34] In our study, we included samples with benign thyroid cytologic findings as negative controls. Although most samples in the benign category did not show any somatic mutations, 4 cases (26.7%) had activating RAS mutations (Fig. 5) . Finding RAS mutations in benign thyroid nodules has been reported by others. 30, 32 RAS activation promotes malignant transformation and subsequent tumor dedifferentiation and may act as an early step in thyroid oncogenesis. 31, 35 However, the overall risk of malignancy in the benign group is low, and this justifies conservative management. Currently, the conservative management for benign nodules includes clinical and/or ultrasound follow-up approximately once every year. 19, 36 Therefore, detecting a RAS mutation in a cytologically benign thyroid nodule may warrant a closer clinical follow-up of these patients. One of the biggest challenges in managing patients with thyroid nodules is the substantial number of indeterminate cytologic diagnoses with varying risks of malignancy (6%-18% for AUS/FLUS to 10%-40% for FN/SFN). 3 In this study, most cases with an indeterminate cytologic diagnosis did not show any somatic mutations; however, 11 cases (35.5%) had somatic mutations in RAS, PTEN, or BRAF. Of the 31 patients in this category, 10 had follow-up surgery that showed a benign colloid nodule (n = 3), PTC (n = 2), follicular variant of PTC (n = 2), follicular adenoma (n = 1), follicular carcinoma (n = 1), or atypical Hürthle cell neoplasm (n = 1; Fig. 6 ). Interestingly, one of the AUS/ FLUS cases in which we detected a low-level BRAF c.1799T>A p.V600E mutation was found to have PTC in a subsequent thyroidectomy specimen. Of the remaining patients, 13 did not have any documented follow-up (including 1 AUS/FLUS patient with a BRAF mutation), 7 were deemed stable on subsequent imaging studies, and 1 was diagnosed with metastatic PTC on subsequent neck lymph node FNA. The detection of clinically relevant somatic mutations, especially BRAF c.1799T>A p.V600E mutations in AUS/FLUS samples, indicates that mutation profiling of these previously discarded supernatant samples not only can provide adequate material for molecular testing but also may identify at-risk patients and improve the diagnostic accuracy of indeterminate thyroid FNA samples. In the suspicious for malignancy cohort, of the 7 patients (58.3%) with a BRAF c.1799T>A p.V600E mutation detected in the supernatant sample, 6 had subsequent surgery showing PTC, and 1 patient declined surgery and was lost to follow-up (Fig. 7) . Two patients without detectable mutations were diagnosed with PTC on subsequent surgery; however, no mutation analysis was performed for the surgical case. A third patient without detectable mutations is still pending surgery. Two patients were diagnosed with PTC, one on a thyroid lobectomy and the other with metastasis to the lung; both cases had an NGS analysis performed on the surgical samples, which showed the same mutation profile as the supernatant samples.
The main concern regarding the use of supernatants from centrifuged FNA samples as a substrate for molecular analysis is the lack of a morphologic correlate that accounts for the tumor fraction in the sample. A recent study reported detecting BRAF mutations in FNA cytologic specimens but not in the corresponding centrifuged supernatant in a subset of its cases. 15 However, the testing methodologies for the FNA cellular material and the supernatant material used in that study were different, and the difference in the analytic sensitivity of the 2 platforms used could explain the discordance seen in the paired samples. In the current study, we show adequate amounts of DNA yield from the FNA supernatant samples, even the samples that were cytologically nondiagnostic. In addition, most of the samples had amplifiable DNA that was successfully sequenced with multiplexed NGS. However, one needs to exert some caution in interpreting negative mutational analysis results from supernatants: the DNA yield of a supernatant sample may not necessarily correlate with the tumor fraction in the sample because DNA from nontumor cells such as macrophages or peripheral blood elements may be contributing to the DNA yield.
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Therefore, in samples with negative results, correlating with the corresponding FNA smears for the presence of an epithelial component may be helpful in identifying cases with potential false-negative results. Importantly, the numbers of somatic mutations detected per sample in our cohort are in keeping with the results from the thyroid TCGA database of whole exome sequencing of paired normal and tumor tissues. 28 Similarly to the TCGA findings, in this study, most samples had 1 somatic mutation detected, and a subset of malignant samples (10% of primary thyroid carcinomas and 20% of metastatic carcinomas) did not have any somatic mutation detected by NGS. Although false-negative results cannot be entirely excluded, it is more likely that these samples harbored other genetic alterations, such as PAX8-PPARγ or RET/PTC rearrangements, that were not included in our sequencing panel. Exploring the feasibility of including fusion genes for an RNA-based assay may be an option for future studies.
To address the possibility of false-negative results, we evaluated a subset of cases with ultrasensitive ddPCR and confirmed the negative results by an orthogonal method. We also compared the mutations detected in the supernatant with the corresponding FNA cytology specimen (smear or cell block) in a subset of patients who showed 100% concordance between the paired samples, including the cases that had no mutations detected (Table 3) . Furthermore, the VAF seen in the supernatant samples closely aligned with that of the FNA cellular material (ie, smear/cell block), and this suggests that the tumor fraction in the supernatants likely indicated the tumor fraction in the cellular component of the aspirate. Collectively, our study provides promising evidence supporting the use of centrifuged supernatant fluids as a surrogate for molecular testing. However, further studies with larger numbers of samples that have no detectable mutations in the supernatant and with follow-up results (either surgical or clinical) available will be needed to determine the negative predictive value of this test.
In fact, in our study, more than half (57.9%) of the FNA cellular samples (ie, smears/cell blocks) failed to yield adequate DNA for mutation analysis. These results are similar to those of a prior study from our laboratory reporting that 49% of FNA specimens (30 of 61) from a variety of sites failed to provide the 10 ng of DNA required for NGS analysis. 37 In contrast, all 156 supernatant samples (including nondiagnostic samples) had a total DNA yield greater than 10 ng (from 4 mL of supernatant), which met our minimal adequacy criteria for NGS DNA input. Our results indicate that centrifuged supernatants from thyroid FNA samples may actually be a superior substrate for molecular testing of thyroid nodules, even when the cytology is scantly cellular and/or inadequate for ancillary testing. Our results also indicate that most DNA fragments present in these centrifuged supernatants have a size of approximately 4750 bp, which is much larger than the size of cell-free DNA. We, therefore, hypothesize that most of the DNA in the supernatant samples is genomic DNA and is likely released from lysed cells into the collection media and fragmented in the process of aspiration and/ or centrifugation. In summary, in this study, we show that these supernatant samples contain substantial amounts of DNA sufficient for mutational testing on NGS platforms, even when the cytology has limited cellularity or is nondiagnostic. Molecular results for clinically relevant genes can improve diagnostic accuracy in cases with indeterminate cytology, provide prognostic/predictive information in malignant cases, and guide overall patient management. The ability to repurpose centrifuged supernatant FNA samples, which are usually discarded, can obviate additional needle passes into specific proprietary media or repeat biopsies due to paucicellular/nondiagnostic aspirations.
